PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system. Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma. Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumour-associated macrophages (TAMs). Here we show that both mouse and human TAMs express PD-1. TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers. TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion. This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatment with checkpoint inhibitors targeting PD-1 or PD-L1 increases phagocytosis and reduces tumor growth [329].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“In human and mouse CRC tumor models, high levels of PD-1 expression on TAM have low tumor phagocytosis”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“Tumor-associated macrophages were also recently shown to express PD-1 in both mice and humans with colorectal cancer and to impair macrophage phagocytosis (59).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cited by
Items 801–900 of 1,001
Zhang, Y., Zhang, J., Zhao, S., Xu, Y., Huang, Y., Liu, S., Su, P., Wang, C., Li, Y., Li, H., et al. (2024) · Theranostics · doi:10.7150/thno.99112 · Cited by 36
Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells
Ahmed, E. N., Cutmore, L. C., & Marshall, J. F. (2024) · Cancers · doi:10.3390/cancers16183186 · Cited by 35
CAR-armored-cell therapy in solid tumor treatment
Liu, Y., Xiao, L., Yang, M., Chen, X., Liu, H., Wang, Q., Guo, M., & Luo, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05903-3 · Cited by 34
Zandberg, D. P., Vujanovic, L. N., Clump, D. A., Isett, B. R., Wang, H., Sica, G., Bao, R., Li, H., Ohr, J. P., Skinner, H. D., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01580 · Cited by 32
Wątek, M., Piktel, E., Wollny, T., Durnaś, B., Fiedoruk, K., Lech‐Marańda, E., & Bucki, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040843 · Cited by 33
Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma
Wirsching, H., Zhang, H., Szulzewsky, F., Arora, S., Grandi, P., Cimino, P. J., Amankulor, N., Campbell, J. S., McFerrin, L. G., Pattwell, S. S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128217 · Cited by 34
Immunotherapy in Hematologic Malignancies
Kansara, R. R., & Speziali, C. D. (2020) · Current Oncology · doi:10.3747/co.27.5117 · Cited by 34
Shannon, V. R., Anderson, R., Blidner, A. G., Choi, J. N., Cooksley, T., Dougan, M. L., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05708-2 · Cited by 36
Immunological Role and Prognostic Value of APBB1IP in Pan-Cancer Analysis
Ge, Q., Li, G., Chen, J., Song, J., Cai, G., He, Y., Zhang, X., Liang, H., Ding, Z., & Zhang, B. (2020) · Journal of Cancer · doi:10.7150/jca.50785 · Cited by 34
Hwang, W. C., Seo, S. H., Kang, M.-J., Kang, R. H., Paolo, G. D., Choi, K., & Min, D. S. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30224 · Cited by 32
Cui, B., Chen, J., Luo, M., Liu, Y., Chen, H., Lü, D., Wang, L., Kang, Y., Feng, Y., Huang, L., et al. (2021) · International Journal of Oral Science · doi:10.1038/s41368-021-00112-w · Cited by 34
Haddad, F., & Daver, N. G. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-x2 · Cited by 33
Xiao, G., Liu, Z., Gao, X., Wang, H., Peng, H., Li, J., Yang, L., Duan, H., & Zhou, R. (2021) · Immunotherapy · doi:10.2217/imt-2020-0262 · Cited by 34
Alhousami, T., Diny, M., Ali, F., Shin, J., Kumar, G., Kumar, V., Campbell, J. D., Noonan, V. L., Hanna, G. J., Denis, G. V., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0310 · Cited by 37
Hussain, K., Liu, R., Smith, R. C. G., Müller, K. T. J., Ghorbani, M., Macari, S. A., Cleary, K. L. S., Oldham, R. J., Foxall, R. B., James, S., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02294-5 · Cited by 36
Cutting edges and therapeutic opportunities on tumor-associated macrophages in lung cancer
Hu, Q., Wu, G., Wang, R., Ma, H., Zhang, Z., & Xue, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1007812 · Cited by 35
The biological roles of CD24 in ovarian cancer: old story, but new tales
Gu, Y., Zhou, G., Tang, X., Shen, F., Ding, J., & Hua, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183285 · Cited by 33
The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment
Zając, A. E., Czarnecka, A. M., & Rutkowski, P. L. (2023) · Cancers · doi:10.3390/cancers15215294 · Cited by 38
Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy
Liu, L., Chen, G., Gong, S., Huang, R., & Fan, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1274547 · Cited by 41
Immune checkpoints and cancer in the immunogenomics era
Park, R. M., Winnicki, M., Liu, E., & Chu, W. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely027 · Cited by 34
Takehara, T., Wakamatsu, E., Machiyama, H., Nishi, W., Emoto, K., Azuma, M., Soejima, K., Fukunaga, K., & Yokosuka, T. (2021) · Communications Biology · doi:10.1038/s42003-021-02111-3 · Cited by 31
Malik, S., Sureka, N., Ahuja, S., Aden, D., Zaheer, S., & Zaheer, S. (2024) · Cell Biology International · doi:10.1002/cbin.12226 · Cited by 36
Zeng, Y., Huang, Y., Tan, Q., Peng, L., Wang, J., Tong, F., & Dong, X. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13413 · Cited by 34
Russell, S. N., Demetriou, C., Valenzano, G., Evans, A., Go, S., Stanly, T. A., Hazini, A., Willenbrock, F. W., Gordon-Weeks, A. N., Mukherjee, S., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-333492 · Cited by 33
Analyzing the impact of threshold strategies on cancer treatment using non-smooth models
Wu, X., Qin, W., & Tang, S. (2025) · Mathematical Biosciences · doi:10.1016/j.mbs.2025.109559 · Cited by 38
Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab
Senoo, S., Ninomiya, T., Makimoto, G., Nishii, K., Kano, H., Watanabe, H., Hata, Y., Kubo, T., Tanaka, T., Hotta, K., et al. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0890-18 · Cited by 31
Radiotherapy as a New Player in Immuno-Oncology
Wang, S.-J., & Haffty, B. G. (2018) · Cancers · doi:10.3390/cancers10120515 · Cited by 31
Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis
Lü, L., Li, Y., Luo, R., Xu, J., Feng, J., & Wang, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00632 · Cited by 31
Promoters and Antagonists of Phagocytosis: A Plastic and Tunable Response
Freeman, S. A., & Grinstein, S. (2021) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-120219-055903 · Cited by 33
Reed, T., Schorey, J. S., & D’Souza‐Schorey, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.746432 · Cited by 31
Kim, C., Lim, M. K., Woodworth, G. F., & Arvanitis, C. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-03973-1 · Cited by 33
Molecular mechanisms and clinical applications of exosomes in prostate cancer
Cui, X., Fu, Q., Wang, X., Xia, P., Cui, X., Bai, X., & Lu, Z. (2022) · Biomarker Research · doi:10.1186/s40364-022-00398-w · Cited by 35
Zhou, S., Lu, J., Liu, S., Shao, J., Liu, Z., Li, J., & Xiao, W. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1166916 · Cited by 38
FBXO38 regulates macrophage polarization to control the development of cancer and colitis
Zheng, X., Jiang, Q., Han, M., Ye, F., Wang, M., Qiu, Y., Wang, J., Gao, M., Hou, F., & Wang, H. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01081-2 · Cited by 32
Martín-Ruiz, A., Fiuza‐Luces, C., Martínez-Martínez, E., Arias, C. F., Gutiérrez, L., Ramírez, M. R., Martín, P., Coronado, M. J., Lucía, A., & Provencio, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-63796-w · Cited by 31
Zhao, S., Wang, Q., Liu, Y., Zhang, P., Ji, W., Xie, J., & Cheng, C. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01688-4 · Cited by 32
The role of macrophages in gastric cancer
Zhang, J., Hu, C., Zhang, R., Xu, J., Zhang, Y., Li, Y., Zhang, S., Pan, S., Cao, M., Qin, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1282176 · Cited by 36
Research progress of serum albumin in the field of drug delivery
Ji, H., Zheng, Z., Li, S., Xiao, X., Tang, W., Zhang, X., Guo, Q., He, Q., Cai, S., Jiang, P., et al. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20240010 · Cited by 37
Immunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.006 · Cited by 31
Raggi, F., & Bosco, M. C. (2020) · Cancers · doi:10.3390/cancers12051337 · Cited by 32
Wu, B., Chiang, H.-C., Sun, X., Yuan, B., Mitra, P., Hu, Y., Curiel, T. J., & Li, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000964 · Cited by 33
Wang, Y., Zhang, X., Xie, X., Chen, W., Li, M., Diao, D., & Dang, C. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1838032 · Cited by 33
The human melanoma proteome atlas—Defining the molecular pathology
Betancourt, L. H., Gil, J., Kim, Y., Doma, V., Çakır, U., Sánchez, A., Murillo, J. R., Kuras, M., Plá, I., Sugihara, Y., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.473 · Cited by 35
Wang, Y.-M., Qiu, J.-J., Qu, X.-Y., Peng, J., Lu, C., Zhang, M., Zhang, M.-X., Qi, X.-L., Lv, B., Guo, J.-J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2034257 · Cited by 30
Geng, Y., Feng, J. X., Huang, H., Wang, Y., Yi, X., Wei, S., Zhang, M., Li, Z., Wang, W., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5270 · Cited by 33
Wen, D., Liang, T., Chen, G., Li, H., Wang, Z., Wang, J., Fu, R., Han, X., Ci, T., Zhang, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202206001 · Cited by 32
Lee, H., Ferguson, A. L., Quek, C. Y. J., Vergara, I. A., da Silva, I. P., Allen, R. O., Gide, T. N., Conway, J. W., Koufariotis, L. T., Hayward, N. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2657 · Cited by 32
Zhan, C., Jin, Y. H., Xu, X., Shao, J., & Jin, C. (2023) · Cancer Medicine · doi:10.1002/cam4.5489 · Cited by 33
Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
Luo, X., Shen, Y., Huang, W., Bao, Y., Mo, J., Yao, L., & Yuan, L. (2023) · Cancer Control · doi:10.1177/10732748231159706 · Cited by 32
Shields, N. J., Peyroux, E. M., Ferguson, A. L., Steain, M. C., Neumann, S., & Young, S. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152035 · Cited by 33
Habib, S., Osborn, G., Willsmore, Z. N., Chew, M. W., Jakubow, S., Fitzpatrick, A., Wu, Y., Sinha, K., Lloyd-Hughes, H., Geh, J. L. C., et al. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2326626 · Cited by 35
Inamura, K., Shigematsu, Y., Ninomiya, H., Nakashima, Y., Kobayashi, M., Saito, H., Takahashi, K., Futaya, E., Okumura, S., Ishikawa, Y., et al. (2018) · Cancers · doi:10.3390/cancers10080252 · Cited by 33
HDACi delivery reprograms tumor-infiltrating myeloid cells to eliminate antigen-loss variants
Nguyen, A., Ho, L., Workenhe, S. T., Chen, L., Samson, J., Walsh, S. R., Pol, J., Bramson, J. L., & Wan, Y. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.040 · Cited by 29
Challenges in validation of combination treatment strategies for CRC using patient-derived organoids
Benboubker, V., Ramzy, G. M., Jacobs, S., & Nowak-Sliwinska, P. M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03173-x · Cited by 32
Emerging insights into the impact of systemic metabolic changes on tumor-immune interactions
Cote, A. L., Munger, C. J., & Ringel, A. E. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115234 · Cited by 29
Harnessing phytochemicals: Innovative strategies to enhance cancer immunotherapy
Zhu, Q., Zhang, R., Zhao, Z., Xie, T., & Sui, X. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101206 · Cited by 37
Zhang, G., Pan, J., Xu, X., Nie, S., Lu, L., Jing, Y., Yang, F., Ji, G., & Xu, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143323 · Cited by 32
Clark, M. L., Simeonov, K. P., Mowel, W. K., Michieletto, M. F., Joannas, L. D., Wright, J. M., Erickson, I., Johnson, L. R., Krishnan, R., de la Fuente‐Núñez, C., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.06.006 · Cited by 33
Fan, C., Zhu, W., Chen, Y., Zhu, W., & Ding, J. (2025) · MedComm · doi:10.1002/mco2.70415 · Cited by 36
HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila
Teng, L., Wang, K., Chen, W., Wang, Y., & Bi, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105086 · Cited by 32
Inhibition of programmed death‐1 decreases neointimal hyperplasia after patch angioplasty
Bai, H., Wang, Z., Li, M., Sun, P., Wei, S., Wang, W., Wang, Z., Xing, Y., Li, J., & Dardik, A. (2020) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34698 · Cited by 31
The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome
Liu, Z., Wu, X., Hwang, S. T., & Liu, J. (2021) · Annals of Dermatology · doi:10.5021/ad.2021.33.6.487 · Cited by 31
Ren, J., Li, L., Yu, B., Xu, E., Sun, N., Li, X., Xing, Z., Han, X., Cui, Y., Wang, X., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09194-z · Cited by 31
Garcia, M. G., Deng, Y., Murray, C. E., Reyes, R. M., Padron, A. S., Bai, H., Kancharla, A., Gupta, H. B., Shen-Orr, S. S., & Curiel, T. J. (2022) · Aging and Cancer · doi:10.1002/aac2.12045 · Cited by 30
Advances in the study of CD47 ‐based bispecific antibody in cancer immunotherapy
Zhang, B., Li, W., Fan, D., Tian, W., Zhou, J., Ji, Z., & Song, Y. (2022) · Immunology · doi:10.1111/imm.13498 · Cited by 32
Nascimento, C. S., Castro, F., Domingues, M., Lage, A. C. P., Alves, É. A. R., Junior, R. D. J. O., de Melo, C. P., Calzavara-Silva, C. E., & Sarmento, B. F. C. C. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122866 · Cited by 29
Effect of tumor-associated macrophages on the pyroptosis of breast cancer tumor cells
Ji, X., Huang, X., Li, C., Guan, N., Pan, T., Dong, J., & Li, L. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01208-y · Cited by 31
Martins, C. P., Rasbach, E., Heppt, M. V., Singh, P. K., Kulcsár, Z., Holzgruber, J., Chakraborty, A., Mucciarone, K., Kleffel, S., Brandenburg, A., et al. (2024) · Science Advances · doi:10.1126/sciadv.adi2012 · Cited by 33
Hollander, P., Amini, R., Ginman, B., Molin, D. L., Enblad, G., & Glimelius, I. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204870 · Cited by 29
Ho, C., Chen, H., Hu, R., & Lee, P. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919843463 · Cited by 31
Macrophage heterogeneity and its interactions with stromal cells in tumour microenvironment
Cao, L., Meng, X., Zhang, Z., Liu, Z., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01201-z · Cited by 32
From mechanism to therapy: the journey of CD24 in cancer
Zhao, K., Wu, C., Li, X., Niu, M., Wu, D., Cui, X., & Hai, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1401528 · Cited by 32
ACSL6-activated IL-18R1–NF-κB promotes IL-18–mediated tumor immune evasion and tumor progression
Di, Y., Wang, Z., Xiao, J., Zhang, X., Ye, L., Wen, X., Qin, J., Lu, L., Wang, X., & He, W. (2024) · Science Advances · doi:10.1126/sciadv.adp0719 · Cited by 32
Akagi, Y., Awano, N., Inomata, M., Kuse, N., Tone, M., Yoshimura, H., Jo, T., Takada, K., Kumasaka, T., & Izumo, T. (2020) · Internal Medicine · doi:10.2169/internalmedicine.3889-19 · Cited by 28
Huang, S., Zhou, N., Zhao, L., Gimple, R. C., Ahn, Y. H., Zhang, P., Wang, W., Shao, B., Yang, H. J., Zhang, Q., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101458 · Cited by 30
Szlosarek, P. W., Phillips, M. M., Pavlyk, I., Steele, J. P. C., Shamash, J., Spicer, J. F., Kumar, S. S., Pacey, S., Feng, X., Johnston, A. L., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100093 · Cited by 28
Management of cell death in parasitic infections
Bosurgi, L., & Rothlin, C. V. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00875-8 · Cited by 30
Single-synapse analyses of Alzheimer’s disease implicate pathologic tau, DJ1, CD47, and ApoE
Phongpreecha, T., Gajera, C. R., Liu, C. C., Vijayaragavan, K., Chang, A. L., Becker, M., Fallahzadeh, R., Fernandez, R., Postupna, N., Sherfield, E., et al. (2021) · Science Advances · doi:10.1126/sciadv.abk0473 · Cited by 28
Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity
Lin, H.-J. L., Liu, Y., Lofland, D., & Lin, J. (2022) · Cancers · doi:10.3390/cancers14020285 · Cited by 31
Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma
Ren, C., Li, J., Zhou, Y., Zhang, S., & Wang, Q. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101367 · Cited by 34
Ferroptosis and Cancer Immunotherapy
Yin, J., Meng, X., Peng, L., Xie, W., Liu, X., He, W., & Li, S. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220509124608 · Cited by 29
Strategies for developing PD-1 inhibitors and future directions
Chen, W., Huang, Y., Pan, W., Xu, M., & Chen, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115113 · Cited by 30
Immune checkpoint molecules in neuroblastoma: A clinical perspective
Pathania, A. S., Prathipati, P., Murakonda, S. P., Murakonda, A. B., Srivastava, A., Avadhesh, A., Byrareddy, S. N., Coulter, D. W., Gupta, S. C., & Challagundla, K. B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.013 · Cited by 29
Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis
Gu, Z., Xu, S., Guo, Z., & Liu, Z. (2022) · Chemical Science · doi:10.1039/d2sc03412c · Cited by 31
Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies
Adams, R., Osborn, G., Mukhia, B., Laddach, R., Willsmore, Z. N., Chenoweth, A. M., Geh, J. L. C., Ross, A. D. M., Healy, C., Barber, L. D., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2127284 · Cited by 31
Kittikulsuth, W., Nakano, D., Kitada, K., Uyama, T., Ueda, N., Asano, E., Okano, K., Matsuda, Y., & Nishiyama, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-28073-6 · Cited by 29
Jiang, J., Huang, H., Chen, R., Lin, Y., & Ling, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1092401 · Cited by 31
Shen, C., Liu, J., Jiao, W., Zhang, X., Zhao, X., Yang, X., & Wang, Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05164-5 · Cited by 31
Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers
Pizzato, H. A., Alonso‐Guallart, P., Woods, J., Jóhannesson, B., Connelly, J. P., Fehniger, T. A., Atkinson, J. P., Pruett‐Miller, S. M., Monsma, F. J., & Bhattacharya, D. (2024) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.12.003 · Cited by 28
Challenges and perspectives in the immunotherapy of Hodgkin lymphoma
Michot, J., Lazarovici, J., Ghez, D., Danu, A., Fermé, C., Bigorgne, A., Ribrag, V., Marabelle, A., & Aspeslagh, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.014 · Cited by 28
Peptide therapeutics and assemblies for cancer immunotherapy
Li, M., Zhao, X., Dai, J., & Yu, Z. (2019) · Science China Materials · doi:10.1007/s40843-019-9451-7 · Cited by 31
The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events
Mihic‐Probst, D., Reinehr, M. D., Dettwiler, S., Kolm, I., Britschgi, C., Kudura, K., Maggio, E. M., Lenggenhager, D. M., & Rushing, E. J. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.152009 · Cited by 29
Dong, Y., Zhang, S., Gao, X., Yin, D., Wang, T., Li, Z., Wan, Z., Wei, M., Luo, Y., Yang, G., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.008 · Cited by 39
Kohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
PD ‐1: A critical player and target for immune normalization
Liu, X., Zhao, A., Xiao, S., Li, H., Li, M., Guo, W., & Han, Q. (2024) · Immunology · doi:10.1111/imm.13755 · Cited by 29
Zhang, C., Liu, Y., Jiang, J., Chen, C., Duan, Z., Su, H., Wang, S., Tian, B., Shi, Y., Xiang, R., et al. (2024) · Theranostics · doi:10.7150/thno.94537 · Cited by 29
Disruption of tumor-intrinsic PGAM5 increases anti-PD-1 efficacy through the CCL2 signaling pathway
Wei, X., Wang, H., Liu, H., Wang, J., Zhou, P., Li, X., He, Y., Li, Y., Han, D. K., Mei, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009993 · Cited by 30
Liu, Y., Ma, J., Ma, Y., Wang, B.-C., Wang, Y., Yuan, J., Zhang, F., Zhao, X., Chen, K., Zhang, X., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010813 · Cited by 28
Griffiths, J. I., Cosgrove, P. A., Medina, E. F., Nath, A., Chen, J., Adler, F. R., Chang, J. T., Khan, Q. J., & Bild, A. H. (2025) · Nature Communications · doi:10.1038/s41467-025-56279-x · Cited by 33
Leung, C. S., Li, J., Xu, F., Wong, A. S. L., & Lui, K. O. (2018) · The FASEB Journal · doi:10.1096/fj.201800449r · Cited by 27
Metadata
- Authors
- Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Yale University (US)
- Corresponding author
- Weissman, Irving L.
- ORCID
- Venue
- Nature
- Published
- 2017-05
- Volume
- 545
- Issue
- 7655
- Pages
- 495-499
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5931375
- OpenAlex
- W2615301036
- Cited by
- 2,247
- References
- 34
- Citations by year
- 2026: 167 · 2025: 261 · 2024: 303 · 2023: 298 · 2022: 309 · 2021: 299 · 2020: 264 · 2019: 158 · 2018: 135 · 2017: 51
- FWCI
- 75.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- Cancer Research Institute
- A.P. Giannini Foundation
- Giannini Foundation of Agricultural Economics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (155336)
- National Institutes of Health (1s10rr026780-01)
- National Cancer Institute (R01CA086017, P30CA124435)
- National Institute of General Medical Sciences (T32GM007365)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR050942)
- National Center for Research Resources (1S10RR02678001, 1S10RR026780, S10 RR026780)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PD-1, tumour-associated macrophages, PD-L1, phagocytosis, immune checkpoint blockade, tumour immunity, cancer immunotherapy, tumour-infiltrating macrophages
- MeSH terms
- Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Neoplasm Staging, Phagocytosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.